Turner's Syndrome Clinical Trial
Official title:
Evaluation De L'Observance Globale Et De La Duree De Traitement Par Zomacton® Avec Le Stylo Transjecteur Zomajet® Etude Pharmaco-Epidemiologique Observationnelle Longitudinale Prospective
The purpose of this strictly observational, prospective, longitudinal study is to evaluate with sufficient precision the rate of overall treatment compliance from one year to 3 years of follow-up of the patients. Somatotropin is indicated in the long-term treatment of children with growth retardation related to a deficiency in secretion of growth hormone and in the long-term treatment of growth retardation related to Turner's syndrome confirmed by chromosomal analysis. These are the two indications of Zomacton® 4 mg and 10 mg injection solution. The use of the Zomajet® needle-free device (Zomajet® 2 Vision, reserved for the administration of Zomacton® 4 mg or of the Zomajet® Vision X needle-free device, reserved for the administration of Zomacton® 10 mg), allows the product to be administered by percutaneous transjection (needle-free) and can be used by the child directly or by the family after an initial training. In April 2004, the CEPP (Commission for the Evaluation of Products and Services) requested a follow-up of the cohort of patients using the Zomajet® 2 Vision system measuring the compliance and duration of use of the device. The number of patients initiated on Zomacton treatment using the Zomajet® needle-free device is estimated to 30. Over a period of inclusion of 3 years, we therefore estimate that 90 patients will be treated. In the cohort studied the patients will be followed-up for 1 year at least and for 3 years at the maximum. The rate of treatment compliance will be evaluated according to the ratio of the actual duration of administration over the total duration recommended by the physician during the observation period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00006334 -
Turner Syndrome: Genotype and Phenotype
|
N/A | |
| Not yet recruiting |
NCT02871986 -
Pubertal Induction in Individuals With Hypogonadism
|
N/A | |
| Completed |
NCT00001221 -
Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome
|
Phase 2 | |
| Completed |
NCT00250250 -
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG
|
Phase 3 | |
| Completed |
NCT00004275 -
Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome
|
Phase 2 | |
| Completed |
NCT00001253 -
The Effects of Estrogen on Cognition in Girls With Turner Syndrome
|
Phase 2 | |
| Completed |
NCT00013546 -
Hormone Replacement Therapy to Treat Turner Syndrome
|
Phase 2 | |
| Terminated |
NCT02018172 -
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
|
N/A | |
| Completed |
NCT01066052 -
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
|
Phase 4 | |
| Completed |
NCT01813630 -
A Clinical Study to Assess the Efficacy and Safety of DA-3002
|
Phase 3 | |
| Completed |
NCT00004274 -
Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome
|
N/A | |
| Completed |
NCT00001343 -
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome
|
Phase 2 | |
| Terminated |
NCT00870220 -
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
|
Phase 1 |